Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: Effect of combination with tobramycin simulating human serum pharmacokinetics

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 4, 2004, Pages 767-771

  Navas, Dominique ^a   Caillon, Jocelyne ^a   Gras Le Guen, Christele ^a   Jacqueline, Cédric ^a   Kergueris, Marie France ^a   Bugnon, Denis ^a   Potel, Gilles ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Amimal models; Continuous infusion; Lowest effective serum concentration

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; IMIPENEM; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; INFUSION PUMP; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SIMULATION; STEADY STATE; VEGETATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; TOBRAMYCIN;

EID: 6344294242     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh381     Document Type: Article

References (44)

1. Reyes, M. P. & Lerner, A. M. (1983). Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Reviews of Infectious Diseases 5, 314-21.
2. Daenen, S. & de Vries-Hospers, H. (1988). Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet i, 937.
3. Fichtenbaum, C. J. & Smith, M. J. (1992). Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem. Clinical Infectious Diseases 14, 353-4.
4. Hilf, M., Yu, V. L., Sharp, J. et al. (1989). Antibiotic therapy for Pseudomonas areuginosa bacteremia: outcome correlations in a prospective study of 200 patients. American Journal of Medicine 87, 540-6.
5. Drusano, G. L. (1990). Human pharmacodynamics of β-lactams, aminoglycosides and their combination. Scandinavian Journal of Infectious Diseases Supplementum 74, 235-48.
6. Craig, W. A. & Ebert, S. C. (1992). Continuous infusion of β-lactam antibiotics. Antimicrobial Agents and Chemotherapy 36 2577-83.
7. Mouton, J. W. & Vinks, A. (1996). Is continuous infusion of β-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. Journal of Antimicrobial Chemotherapy 38, 5-15.
8. Tunkel, A. R. & Scheld, W. M. (1989). Applications of therapy in animal models to bacterial infection in human disease. Infectious Disease Clinics of North America 3, 441-59.
9. Carbon, C. (1993). Experimental endocarditis: a review of its relevance to human endocarditis. Journal of Antimicrobial Chemotherapy 31, Suppl. D, 71-85.
10. Lorian, V. & Burns, L. (1990). Predictive value of susceptibility tests for the outcome of antibacterial therapy. Journal of Antimicrobial Chemotherapy 25, 175-81.
11. Greenwood, D. (1981). In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance. Journal of Infectious Diseases 144, 380-5.
12. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Document M7-A4. NCCLS, Villanova, PA, USA.
13. Perlman, B. B. & Freedman, L. R. (1971). Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale Journal of Biology and Medicine 44, 206-13.
14. Stewart, J. T., Maddox, F. C. & Warren, F. W. (1999). Stability of cefepime hydrochloride in polypropylene syringes. American Journal of Health-System Pharmacy 56, 1134.
15. Baririan, N., Chanteux, H., Viaene, E. et al. (2003). Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. Journal of Antimicrobial Chemotherapy 51, 651-8.
16. Sprauten, P. F., Beringer, P. M., Louie, S. G. et al. (2003). Stability and antibacterial activity of cefepime during continuous infusion. Antimicrobial Agents and Chemotherapy 47 1991-4.
17. Viaene, E., Chanteux, H., Servais, H. et al. (2002). Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrobial Agents and Chemotherapy 46, 2327-32.
18. Potel, G., Caillon, J., Xiong, Y. Q. et al. (1995). La concentration sérique critique des antibiotiques: un outil thérapeutique et un moyen d'évaluation comparative. Presse Medicale 24, 750-2.
19. Bugnon, D., Potel, G., Caillon, J. et al. (1998). In vivo simulation of human pharmacokinetics in the rabbit. Bulletin of Mathematical Biology 60, 545-67.
20. Myers, C. M. & Blumer, J. L. (1984). Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography. Antimicrobial Agents and Chemotherapy 26, 78-81.
21. Patel, K. B., Nicolau, D. P., Nightingale, C. H. et al. (1995). Continuous infusion of β-lactam antibiotics: a rational dosing approach. Connecticut Medicine 59, 471-4.
22. Vondracek, G. T. (1995). β-Lactam antibiotics: is continuous infusion the preferred method of administration? Annals of Pharmacotherapy 29, 415-24.
23. Ronchera-Oms, C. L., Gregorio, S. & Sanllehi, N. (1997). Should continuous infusion of β-lactam antibiotics be the first-line approach? Journal of Clinical Pharmacy and Therapeutics 22, 159-61.
24. MacGowan, A. P. & Bowker, K. E. (1998). Continuous infusion of β-lactam antibiotics. Clinical Pharmacokinetics 35, 391-402.
25. Turnidge, J. D. (1998). The pharmacodynamics of β-lactams. Clinical Infectious Diseases 27, 10-22.
26. Grant, E., Nicolau, D. P., Nightingale, C. H. et al. (1999). Continuous infusion of β-lactam antibiotics. Connecticut Medicine 63, 275-7.
27. Cappelletty, D. M., Kang, S. L., Palmer, S. M. et al. (1995). Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrobial Agents and Chemotherapy 33, 1797-801.
28. Manduru, M., Mihm, L. B., White, R. L. et al. (1997). In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 41, 2053-6.
29. Mouton, J. W. & den Hollander, J. G. (1994). Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrobial Agents and Chemotherapy 38, 931-6.
30. Lemmen, S. W., Engels, I. & Daschner, F. D. (1997). Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers. Journal of Antimicrobial Chemotherapy 39, 841-2.
31. Robaux, M. A., Dube, L., Caillon, J. et al. (2001). In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. Journal of Antimicrobial Chemotherapy 47, 617-22.
32. Xiong, Y. Q., Potel, G., Caillon, J. et al. (1994). Determination of the in vivo efficacious serum concentration of ceftazidime administered as a continuous iv infusion on an experimental model of P. aeruginosa rabbit endocarditis model. In Program and Abstracts of the Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract A-88, p. 118. American Society for Microbiology, Washington, DC, USA.
33. Tam, V. H., McKinnon, P. S., Akins, R. L. et al. (2002). Pharmacodynamics of cefepime in patients with Gram-negative infections. Journal of Antimicrobial Chemotherapy 50, 425-8.
34. Schentag, J. J., Gilliland, K. K. & Paladino, J. A. (2001). What have we learned from pharmacokinetic and pharmacodynamic theories? Clinical Infectious Diseases 32, Suppl. 1, S39-46.
35. Lipman, J., Wallis, S. C. & Rickard, C. (1999). Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrobial Agents and Chemotherapy 43, 2559-61.
36. Tessier, P. R., Nicolau, D. P., Onyeji, C. O. et al. (1999). Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy 45, 284-95.
37. Keil, S. & Wiedemann, B. (1997). Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrobial Agents and Chemotherapy 41, 1215-9.
38. Flückiger, U., Segessenmann, C. & Gerber, A. U. (1991). Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrobial Agents and Chemotherapy 35, 1905-10.
39. Fantin, B., Leggett, J., Ebert, S. et al. (1991). Correlation between in vitro and in vivo activity of antimicrobial agents against Gram-negative bacilli in a murine infection model. Antimicrobial Agents and Chemotherapy 35, 1413-22.
40. Cozens, R. M., Markiewicz, Z. & Tuomanen, E. (1989). Role of autolysins in the activities of imipenem and CGP 31608, a novel penem, against slowly growing bacteria. Antimicrobial Agents and Chemotherapy 33, 1819-21.
41. Xiong, Y. Q., Yeaman, M. R. & Bayer, A. S. (1999). In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrobial Agents and Chemotherapy 43, 1111-7.
42. Mouton, J. W., van Ogtrop, M. L., Andes, D. et al. (1999). Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrobial Agents and Chemotherapy 43 2473-8.
43. Ariano, R. E., Kassum, D. A., Meatherall, R. C. et al. (1992). Lack of in vitro inactivation of tobramycin by imipenem/cilastatin. Annals of Pharmacotherapy 26, 1075-7.
44. Aronoff, G. R., Brier, R. A., Sloan, R. S. et al. (1990). Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function. Antimicrobial Agents and Chemotherapy 34, 1139-42.